1. Home
  2. Stocks
  3. Glenmark Share Price

Glenmark Pharmaceuticals Share Price

Pharmaceuticals Large Cap

₹1,725.15 +25.9 (1.52%)

05 Nov, 2024 20:56

SIP TrendupStart SIP in GLENMARK

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹1,669
  • High
  • ₹1,737
  • 52 Week Low
  • ₹722
  • 52 Week High
  • ₹1,831
  • Open Price₹1,698
  • Previous Close₹1,699
  • Volume1,018,795

Investment Returns

  • Over 1 Month + 3.76%
  • Over 3 Month + 19.55%
  • Over 6 Month + 63.79%
  • Over 1 Year + 131.07%
SIP Lightning

Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!

Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -37.1
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 48,682
  • P/B Ratio
  • 6.2
  • Average True Range
  • 52.17
  • EPS
  • 50.5
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 1.81
  • RSI
  • 54.16
  • MFI
  • 30.38

Glenmark Pharmaceuticals Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations2,296.882,148.221,365.102,233.422,144.38
Total Income From Operations2,329.542,148.221,365.102,233.422,144.38
P/L Before Interest, Excpt. Items & Tax633.661,231.3223.39467.22485.61
P/L Before Exceptional Items & Tax618.311,147.93-50.22409.04423.67
P/L After Tax from Ordinary Activities453.734,613.70-20.41302.35271.66
Net Profit/Loss For the Period453.734,613.70-20.41302.35271.66
IndicatorMar 24Mar 23
Revenue From Operations [Gross]7,649.768,019.67
Revenue From Operations [Net]7,649.768,019.67
Total Operating Revenues7,891.128,220.66
Total Revenue9,059.149,206.60
Total Expenses7,128.737,138.86
Profit/Loss Before Tax7,000.751,571.87
Profit/Loss For The Period5,167.291,208.77
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-495.451,474.06
Net Cash Used In Investing Activity3,197.19-431.47
Net Cash Used in Finance Activity-2,666.45-978.50
Net Inc/Dec In Cash And Equivalent35.2764.05
Cash And Equivalent End Of Year127.9692.70
IndicatorMar 24Mar 23
Total Share Capital28.2228.22
Total Non-Current Liabilities154.393,066.69
Total Current Liabilities4,289.393,641.77
Total Capital And Liabilities27,414.3924,585.92
Total Non-Current Assets22,732.9220,200.75
Total Current Assets4,681.474,385.18
Total Assets27,414.3924,585.92
Indicator20242023
EBIT Margin (%)27.9727.66
Return On Capital Employed (%)9.5410.86
Return On Equity (%)22.496.76
Long Term Debt To Equity (%)0.0014.88
Book Value/Share (INR)814.07633.57
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations3,223.303,062.952,506.703,207.383,401.60
Total Income From Operations3,244.193,062.952,506.703,207.383,401.60
P/L Before Interest, Excpt. Items & Tax501.921,126.17-310.31322.53497.43
P/L Before Exceptional Items & Tax462.33977.61-444.66201.07385.43
P/L After Tax from Ordinary Activities340.24-1,238.65-449.58-180.30173.13
Net Profit/Loss For the Period340.24-1,214.27-330.82-61.56173.13
IndicatorMar 24Mar 23
Revenue From Operations [Gross]11,813.1012,725.43
Revenue From Operations [Net]11,813.1012,725.43
Total Operating Revenues11,813.1012,990.11
Total Revenue12,653.0913,306.90
Total Expenses11,715.6411,672.59
Profit/Loss Before Tax36.50868.45
Profit/Loss For The Period-1,433.52377.40
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-265.44625.39
Net Cash Used In Investing Activity4,560.89-528.49
Net Cash Used in Finance Activity-3,906.13-77.46
Net Inc/Dec In Cash And Equivalent215.2432.50
Cash And Equivalent End Of Year1,658.271,443.03
IndicatorMar 24Mar 23
Total Share Capital28.2228.22
Total Non-Current Liabilities692.494,486.89
Total Current Liabilities5,818.595,045.53
Total Capital And Liabilities14,358.6219,371.68
Total Non-Current Assets6,930.549,497.96
Total Current Assets7,428.089,873.72
Total Assets14,358.6219,371.68
Indicator20242023
EBIT Margin (%)12.3015.27
Return On Capital Employed (%)17.0113.84
Return On Equity (%)-19.133.13
Long Term Debt To Equity (%)0.0040.66
Book Value/Share (INR)278.09348.70

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,725.15
+ 25.9 (1.52%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹1,704.64
  • 50 Day
  • ₹1,669.21
  • 100 Day
  • ₹1,550.42
  • 200 Day
  • ₹1,344.44

Resistance and Support

1710.52 Pivot Speed
  • R3 1,820.43
  • R2 1,778.92
  • R1 1,752.03
  • S1 1,683.63
  • S2 1,642.12
  • S3 1,615.23

Is Glenmark Pharmaceuticals Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Pharmaceuticals Ltd. is a global, research-driven pharmaceutical company with a focus on respiratory, dermatology, and oncology. It operates in over 80 countries with 10 manufacturing facilities, providing branded, generics, and specialty products to improve patient outcomes worldwide. Glenmark Pharms. (Nse) has an operating revenue of Rs. 12,021.22 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -19% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 34% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 32 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-24 Audited Results & Final Dividend
2024-02-14 Quarterly Results
2023-11-10 Quarterly Results

Glenmark Pharmaceuticals F&O

Glenmark Pharmaceuticals Shareholding Pattern

46.65%
11.41%
0.7%
23.05%
0%
13.6%
4.59%
  • NSE Symbol
  • GLENMARK
  • BSE Symbol
  • 532296
  • Chairman & Managing Director
  • Mr. Glenn Saldanha
  • ISIN
  • INE935A01035

Glenmark Pharmaceuticals FAQs

Glenmark Pharmaceuticals share price is ₹1,725 As on 05 November, 2024 | 20:42

The Market Cap of Glenmark Pharmaceuticals is ₹48681.7 Cr As on 05 November, 2024 | 20:42

The P/E ratio of Glenmark Pharmaceuticals is -37.1 As on 05 November, 2024 | 20:42

The PB ratio of Glenmark Pharmaceuticals is 6.2 As on 05 November, 2024 | 20:42

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.